Cure of Breast Cancer Stage III: Discovering Inflammation Inhibitors as a Novel Approach to Treatment of Triple Negative Breast Cancer Using 3-D Organoid Culture
ISEF · 2020 Biomedical and Health Sciences
Overview
Triple negative breast cancer (TNBC) has a higher mitotic index compared to other types of breast cancer yet Ki-67 values are still being used, despite an unclear mechanism. Here we found that the gene Cell-Division Cycle 20 (CDC20), an essential mitotic factor, was highly expressed in TNBC cell lines by using a NCBI GEO database. CDC20 was also negatively correlated with TNBC metastasis and recurrence. CDC20 deficiency results in the decreasing of TNBC cancer cell growth and migration, and mitosis inhibitors blocked TNBC cancer cells growth and metastasis. Interestingly, CDC20 stability is regulated by tumor necrosis factor, alpha-induced protein 3 (TNFAIP3 /A20). CDC20 expression show positive correlation with A20 in TNBC patient samples but not HR positive or HER2 breast cancer patients. A20 deficiency also inhibits cell migration and invasion through the decreasing of CDC20 protein level. Our findings uncover a critical role of the A20-CDC20 axis in tumor growth and metastasis of TNBC and suggest A20 or CDC20 is a novel therapeutic target in TNBC.
Competition history
- ISEF 2020
Resources
Related projects
ISEF · 2023
Cure of Breast Cancer-Year 6: Novel Approaches in the Therapy of Metastatic Breast Cancer Using Clinical Databases and 3D Organoid Model
ISEF · 2022
Cure of Breast Cancer - Year 5: A Novel Approach to Treating Hormonal Breast Cancer Using Diabetic Medication Through Clinical Database and 3D ex vivo Model
ISEF · 2025
Single-Cell Analysis Based Identification of Unique Markers and Metastasis Mechanism in Triple-Negative Breast Cancer
ISEF · 2024
Discovering the Oncogenic Addiction of CD47 in Breast Cancer
Closest projects by meaning, across every fair and year in the corpus.
Source: Regeneron International Science and Engineering Fair